Status:
COMPLETED
Synaptic Density and Progression of Huntington's Disease.
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Conditions:
Huntington Disease
Eligibility:
All Genders
20-75 years
Phase:
NA
Brief Summary
AIM: To assess synaptic density and to investigate the potential relationship of regional synaptic loss with motor and non-motor symptoms and with disease progression in the human brain in vivo in pat...
Eligibility Criteria
Inclusion
- Age 20-75 years.
- Capacity to understand the informed consent form.
- For HD group: CAG repeat expansion in HTT ≥ 40.
- Premanifest HD mutation carriers:
- \* No clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score \< 4.
- Early manifest HD patients:
- Clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score = 4.
- UHDRS-TFC score 7 or higher (Shoulson-Fahn stage 1 and 2).
Exclusion
- neuropsychiatric diseases other than HD
- major internal medical diseases
- white matter lesion load on FLAIR Fazekas score 2 or higher or other relevant MRI abnormalities
- history of alcohol abuse or current alcohol abuse (chronic use of more than 15 units per week) or drug abuse
- contraindications for MR
- pregnancy
- previous participation in other research studies involving ionizing radiation with \>1 mSv in the previous 12 months.
Key Trial Info
Start Date :
January 14 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 5 2022
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT04701580
Start Date
January 14 2020
End Date
October 5 2022
Last Update
November 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UZ Leuven
Leuven, Vlaams-Brabant, Belgium, 3000